TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17169543
Drug: Kytta-Salbe f
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kytta-Salbe f (comfrey root extract ointment)
Study: 3303813
Drug: Low-dose prostaglandin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prostaglandin F2 alpha (PGF2 alpha)
Study: 19256728
Drug: Psychiatric Music
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric Music Therapy
Study: 17580544
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment applied on lumbar paravertebral muscle
Study: 20226302
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg, 10 mg, 20 mg
Study: 16650535
Drug: Diluted epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted epinephrine injection alone (n = 53)
Study: 26811189
Drug: Regional blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional blocks (bilateral CNV2 and CNV3 divisions of the trigeminal nerve) with local anaesthesia containing 1/100,000 epinephrine and 10 ml 0.5% levobupivacaine.
Study: 3069774
Drug: Intravesically administered
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesically administered Cetiprin (emepronium bromide)
Study: 21790621
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (RBCs if Hb concentration was 70 g/L or less intraoperatively during CPB and 75 g/L or less postoperatively)
Study: 7661265
Drug: Washout with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washout with lactated Ringer's solution
Study: 17019629
Drug: Weekly assessments
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly assessments
Study: 11276371
Drug: GM-CSF followed
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF followed by G-CSF
Study: 23806459
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 μg once daily
Study: 17049710
Drug: Biological threat
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological threat stimuli (CS+) directed towards participants
Study: 31596648
Drug: Ria Treatment
Normalized name: Riax
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ria Treatment Platform (RTP)
Study: 16409425
Drug: 2-weekly regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-weekly regimen of gemcitabine (1250 mg/qm, day 1) and paclitaxel (120 mg/qm, day 2)
Study: 18281266
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with 3 MU s.c. of IFNalpha2a plus DTIC 850 mg/m(2) every 4‐8 weeks for 2 years (Arm B)
Study: 25287554
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia
Study: 17028353
Drug: sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual misoprostol
Study: 17028353
Drug: oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxytocin infusion after artificial rupture of membranes
Study: 31765988
Drug: Xelox +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xelox + AZD8931 (20 mg bd with 4/3 schedule)
Study: 9540877
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for 2 weeks
Study: 19300380
Drug: Epidural Steroids
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Steroids
Study: 8158539
Drug: Low-dose daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose daily TMP-SMX
Study: 363977
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of clomipramine in a single bedtime dosage
Study: 9352390
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (180 mg diltiazem-HCl)
Study: 26492924
Drug: Online haemodiafiltration
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online haemodiafiltration (HDF) with high delivered convection volume (>23 L per 1.73 m² BSA per session)
Study: 27482783
Drug: Control implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implant
Study: 19212238
Drug: Laser-Lok (LL)
Normalized name: Lokara
DrugBank: Desonide (DB01260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laser-Lok (LL) implant
Study: 8889115
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g creatine daily
Study: 24029539
Drug: Long-term group
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term group therapy (80 weekly, 90 min sessions)
Study: 2156976
Drug: Veterans Administration
Normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veterans Administration (VA) Medical Center
Study: 3086203
Drug: Vasopressin plus
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin plus sublingual nitroglycerin (0.6 mg every 30 min for 6 hr)
Study: 22422082
Drug: Ozone nano-bubble
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone nano-bubble water (NBW3) irrigation as an adjunct to mechanical debridement
Study: 417581
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g of iopronic acid
Study: 14996516
Drug: Epinastine hydrochloride
Normalized name: Epinastine Hydrochloride
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epinastine hydrochloride 0.05% ophthalmic solution
Study: 19618992
Drug: Simvastatin and
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin and L-carnitine
Study: 11106838
Drug: High 2-h
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High 2-h OGTT value (>9.0 mmol/l)
Study: 6135430
Drug: GP 55
Normalized name: Zotex-GP 550mg-8.5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP 55 129 (4 mg)
Study: 27514629
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical exercise training with treatment as usual (TAU)
Study: 16466609
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 0.5 mg/2 mL bid
Study: 16466609
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) 20 mg/2 mL tid
Study: 19853947
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy
Study: 10599951
Drug: Deramciclane 10
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane 10 mg
Study: 11455373
Drug: Preemptive ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preemptive ibuprofen therapy (400 mg taken orally 1 hour before separator placement and 400 mg taken orally 6 hours after the initial dose)
Study: 31613055
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells (MSCs) therapy (2 intravenous doses of 2×10^8 cells every 3 months)
Study: 23113543
Drug: Oxaliplatin combined
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin combined with 5-fluorouracil chemotherapy or Xeloda
Study: 19778495
Drug: Adjunctive olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive olanzapine (5 to 20 mg/d)
Study: 9695137
Drug: Co-syntropin (ACTH1-24)
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-syntropin (ACTH1-24) 0.25 mg
Study: 25358867
Drug: Oral paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral paliperidone extended release (Pali ER)
Study: 16287344
Drug: 5.0 g
Normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g Cr + 18 g dextrose + 4 g of sodium and potassium phosphates (CrP)
Study: 28844193
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with dabigatran (150 mg twice daily)
Study: 10902797
Drug: Leptin levels
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin levels in serum (30.3 +/- 14.8 ng/mL)
Study: 384858
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of treatment with trimethoprim/sulfamethoxazole
Study: 384858
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of treatment with trimethoprim/sulfamethoxazole
Study: 27590374
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
Study: 10802077
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous cefazolin
Study: 21227624
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) therapy
Study: 7621634
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g human intravenous immunoglobulin (IVIg) every three weeks
Study: 1870380
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rifampicin 40 mg/K bodyweight
Study: 1870380
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rifampicin 1500 mg followed by one year of daily dapsone 100 mg
Study: 20979799
Drug: Inhaled tiotropium
Normalized name: tiotropium Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tiotropium 18 µg once daily
Study: 2343912
Drug: 16-week treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-week treatment conditions (specifics not provided)
Study: 7003855
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) lotion
Study: 22825036
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no I-131 therapy)
Study: 22825036
Drug: I-131 therapy
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-131 therapy (11.1 GBq or more)
Study: 18285589
Drug: Biannual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual mass azithromycin administration
Study: 8644690
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g FOS/d
Study: 6121479
Drug: Intravenous atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atenolol (5 mg) followed by oral atenolol (50 mg)
Study: 12368393
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g FOS + 1 x 10(9) cfu LAC
Study: 10404451
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg once daily
Study: 19117316
Drug: OK-432 immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 immunotherapy (for mixed macrocystic-microcystic LM)
Study: 3320932
Drug: Needle wiped
Normalized name: Vagisil Wipes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle wiped with sterile gauze before injection (Group 2)
Study: 3320932
Drug: Needle changed
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle changed before injection (Group 1)
Study: 18797097
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) + alpha-tocopherol (AT)
Study: 31180480
Drug: Oral pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin during the perioperative period
Study: 27128837
Drug: GSK961081 800 µg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GSK961081 800 µg and FP 500 µg as a blend formulation
Study: 6873137
Drug: Scopolamine 6
Normalized name: scopolamine 6.67 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 6 micrograms/kg (intravenous)
Study: 31926883
Drug: Trimethoprim-Sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-Sulfamethoxazole (TMP-SMZ) 160 mg/800 mg twice daily for 45 days followed by 1 dose every other day for 311 days
Study: 21526889
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg alone
Study: 10969672
Drug: High-risk coronary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk coronary artery bypass graft without preoperative intraaortic balloon pump therapy
Study: 27859395
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid at a dosage of 10 mg/kg, administered 3-14 hours preoperatively
Study: 1356311
Drug: xamoterol 100
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol 100 mg two times a day
Study: 24925090
Drug: all active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all active treatments
Study: 20550533
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg once daily for 36 weeks
Study: 2468862
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg clonidine (intravenously)
Study: 12381902
Drug: Cisplatin 65
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 65 mg/m2 and methotrexate 500 mg/m2 on day 1 and Levofolinic acid 250 mg/m2 and 5‐fluorouracil 800 mg/m2 on day 2 (arm B)
Study: 1608219
Drug: Lipostabil treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipostabil treatment
Study: 3910730
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of piperacillin, netilmicin and cefotaxime
Study: 15523323
Drug: Low-dose enalapril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose enalapril
Study: 8328566
Drug: Sustained-release alprazolam
Normalized name: alprazolam Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release alprazolam
Study: 11405162
Drug: Intensive multidisciplinary
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multidisciplinary training & treatment course (ISBP)
Study: 3691273
Drug: Oral cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cisapride
Study: 9345414
Drug: Cladribine treatment
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine treatment
Study: 8155071
Drug: Active Low
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Low Energy Emission Therapy (LEET)
Study: 8155071
Drug: Inactive Low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive Low Energy Emission Therapy (LEET)
Study: 26330424
Drug: Pre-operative statin
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative statin therapy
Study: 31369676
Drug: Quad-helix treatments
Normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quad-helix treatments in general dentistry (QHG)
Study: 2501032
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch (20 cm2)
Study: 2501032
Drug: All patch
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patch sizes
Study: 28832429
Drug: Transdermal 17β-estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17β-estradiol (t-E2)
Study: 3720176
Drug: Intravenous nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nifedipine (4.5 mg in 45 minutes)
Study: 10978398
Drug: Erythropoietin doses
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin doses in experimental group
Study: 1285936
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide daily
Study: 11998963
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (conjugated equine estrogens 0.625 mg/d + medroxyprogesterone acetate 10 mg/d)
Study: 2678520
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) - 25 mg
Study: 31142156
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) with conjugated estrogens/medroxyprogesterone acetate (0.30 mg/1.5 mg/d)
Study: 29390421
Drug: Celecoxib-based chemotherapy
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib-based chemotherapy (in patients with positive COX-2)
Study: 18439766
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (PORT) in the observation arm
Study: 17030751
Drug: Motor Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor Activity Log (MAL) treatment group
Study: 10088733
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle solution administered four times daily for 14 days
Study: 10750765
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aprotinin
Study: 18155200
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for complex congenital anomalies (e.g., unicornuate uterus, uterus didelphys)
Study: 6398510
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dihydroergotamine + 5000 U heparin
Study: 6398510
Drug: 5000 U
Normalized name: lipase 5000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 U heparin alone (controls)
Study: 7223302
Drug: Albumin therapy
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin therapy
Study: 20391509
Drug: Denosumab 180
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 180 mg
Study: 8733039
Drug: Felodipine 2.5
Normalized name: felodipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 2.5 mg once daily
Study: 20876405
Drug: Pine bark
Normalized name: pine bark extract
DrugBank: Maritime pine extract (DB15786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pine bark extract (200 mg/day)
Study: 19150139
Drug: Oxycodone/acetaminophen (O/A)
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone/acetaminophen (O/A)
Study: 6874173
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of potassium‐magnesium aspartate over a 24‐h period
Study: 6874173
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of potassium‐magnesium aspartate
Study: 19378582
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (2.5 microg.kg(‐1))
Study: 1706282
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg of octreotide acetate subcutaneously before pancreatography
Study: 30873657
Drug: Acetazolamide therapy
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide therapy for 6 months